Accordingly, our previous study showed that the PLK1/c-Myc pathway mediates resistance to KRASG12C inhibitors in NSCLC, and co-inhibition of PLK1 and KRASG12C synergistically suppresses tumor growth and overcomes this resistance [47]. The gene discussed is MYC; the disease is neoplasm.